Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Shire plc : Director/PDMR Shareholding

Shire plc
Posted on: 09 Aug 17
  August 29, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transaction by person discharging managerial responsibilities  
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a)NameJoanne Cordeiro
2. Reason for the notification
a)Position / statusChief Human Resources Officer - PDMR
b)Initial notification / amendmentInitial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")

Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of Restricted Stock Units in respect of notional ADSs awarded under the Shire Long Term Incentive Plan 2015 in recognition of promotion to Executive Committee membership. Subject to continued service, 50% of the award will vest on August 24, 2019, and 50% will vest on August 24, 2020.
c)Price(s) and volume(s)Price(s)Volume(s)
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e)Date of the transactionAugust 24, 2017
f)Place of the transactionN/A


Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:


Investor Relations   
Ian Karp +1 781 482 9018
Robert Coates +44 1256 894874
Lisa 617 588 8607
Debbi Ford   +1 617 949 9083




About Shire


Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.


Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Shire plc via GlobeNewswire

Last updated on: 30/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.